Kaitlyn D’Onofrio

DocwireNews

The Food and Drug Administration (FDA) this week announced its approval for romosozumab-aqqg (Evenity) to treat osteoporosis in postmenopausal women at high risk for fracture. The medication comes with a boxed warning for possible increased risk of heart attack, stroke, and cardiovascular death. 
“Today’s approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk,” said Hylton V. Joffe, mD, MMSc., director of the Center for Drug Evaluation and Research’s Division of Bone, Reproductive and Urologic Products, in a statement. “But Evenity may increase the risk of heart attack, stroke and cardiovascular death so it’s important to carefully select patients for this therapy, which includes avoiding use in patients who have had a heart attack or stroke within the previous year.” 
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/Amgen?src=hash&amp;ref_src=twsrc%5Etfw">#Amgen</a> <a href="https://twitter.com/hashtag/Evenity?src=hash&amp;ref_src=twsrc%5Etfw">#Evenity</a> Most Osteoporosis Drugs Don’t Build Bone. This One Does. <a href="https://t.co/iBocngGvnL">https://t.co/iBocngGvnL</a>
&mdash; Claude-H Volmar, PhD (@chvolmar) <a href="https://twitter.com/chvolmar/status/1115790679425396736?ref_src=twsrc%5Etfw">April 10, 2019</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
Romosozumab-aqqg was tested in two clinical trials that included a total of more than 11,000 women with postmenopausal osteoporosis. The first trial compared one-year efficacy of romosozumab-aqqg to placebo and found that it reduced the risk of new vertebral fracture by 73% compared to placebo; this continued over the second year as well when the medication was followed by a year of denosumab—another osteoporosis therapy—compared to placebo followed by denosumab. The second trial compared romosozumab-aqqg to alendronate—another osteoporosis therapy—and found that one year of romosozumab-aqqg reduced new vertebral fracture risk by 50% compared to two years of alendronate. It was in this trial—not the placebo trial—where an increased risk was observed for cardiovascular death, heart attack, and stroke. Romosozumab-aqqg is therefore not indicated for patients who have had a heart attack or stroke within the previous year. 
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Consumer health group warns of risks with new osteoporosis drug, &quot;advises women to talk with their provider about other less risky and cheaper treatments, and consider forgoing the heart health minefield that accompanies Evenity.&quot; <a href="https://t.co/abt9ohf0w8">https://t.co/abt9ohf0w8</a>
&mdash; Liz Szabo (@LizSzabo) <a href="https://twitter.com/LizSzabo/status/1116004992714989575?ref_src=twsrc%5Etfw">April 10, 2019</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
“Health care professionals should also consider whether the benefits of Evenity outweigh its risks in those with other risk factors for heart disease and should discontinue Evenity in any patient who experiences a heart attack or stroke during treatment,” according to the FDA. Side effects associated with romosozumab-aqqg included joint pain, headache, and injection site reactions, the FDA noted.  
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
FDA Approves Evenity for Postmenopausal Women at High Risk for Fracture &#8211; <a href="https://t.co/ylme8KRYdH">https://t.co/ylme8KRYdH</a>
&mdash; Dataemia (@Dataemia) <a href="https://twitter.com/Dataemia/status/1116348495974166529?ref_src=twsrc%5Etfw">April 11, 2019</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
The Food and Drug Administration on Tuesday approved an osteoporosis drug that represents the first new treatment approach in nearly two decades Evenity is the brand name.<a href="https://t.co/TmrCjXmllf">https://t.co/TmrCjXmllf</a><a href="https://twitter.com/CaverStem?ref_src=twsrc%5Etfw">@CaverStem</a>
&mdash; Elias Said, MD, FACEP (@MdFacep) <a href="https://twitter.com/MdFacep/status/1115986191134777346?ref_src=twsrc%5Etfw">April 10, 2019</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Good news for women. Evenity: another option for osteoporosis; a novel monoclonal antibody, although with noted concerns of risk CVD. <a href="https://twitter.com/MsMedicine?ref_src=twsrc%5Etfw">@msmedicine</a> FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture <a href="https://t.co/r8iQx2KuqD">https://t.co/r8iQx2KuqD</a>
&mdash; Lisa Larkin MD FACP (@LisaLarkinMD) <a href="https://twitter.com/LisaLarkinMD/status/1115964141611646976?ref_src=twsrc%5Etfw">April 10, 2019</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Jordana Jampel

Eight Contributing Factors to Increasing Heart Disease Incidence in Some Global Regions

Stroke

New Findings on Myelin Mechanism Involved in Genetically Based Autism

Neurodivergent

AGA Guideline Update on Pharmacologic Ulcerative Colitis Treatment

Gastroenterology

Latest News

FDA Approves Osteoporosis Drug for Postmenopausal Women, Warns About Heart Risks

Rheumatology

The Food and Drug Administration (FDA) this week announced its approval for romosozumab-aqqg (Evenity) to treat osteoporosis in postmenopausal women at high risk for ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe